ClinicalTrials.gg
RecruitingNCT07616154Updated Nov 12, 2026

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

A Phase 2 interventional study of Cyclophosphamide 50mg and Abatacept in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
Up to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing cyclophosphamide in Anemia, Sickle Cell — 3 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Anemia, Sickle Cell.

Planned enrollment
6th of 19
45 · median 23
Started
2026
the only one that year
Phase 2
11 of 19
3 open now
Registered
19th of 19
by date
Lead sponsor
3 of 19
St. Jude Children's Research Hospital

Among the 19 studies testing cyclophosphamide in Anemia, Sickle Cell, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 11 in phase 2, and was the 19th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

3 of the 19 studies testing cyclophosphamide in Anemia, Sickle Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: Up to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing cyclophosphamide in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD.

Primary Objective:

- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD.

Secondary Objectives:

  • Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD.
  • Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD.
  • Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.
03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell
  • Hematopoietic Cell Transplant
04

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Transplant Recipient

  • Age less than or equal to 22 years.
  • Patients without a suitable HLA-matched sibling donor but with a suitable single haplotype matched (≥ 3 of 6) family member donor. Potential donors do not need to undergo eligibility determination prior to the recipients enrolling on the study. As long as a potential donor is identified and willing to donate hematopoietic progenitor cells, recipients can enroll on the study.
  • Patients with SCD (any genotype) who meet any ONE of the following criteria:
  • History of an abnormal transcranial Doppler measurement defined as TCD velocity ≥200 cm/sec by the non-imaging technique (or ≥185 cm/sec by the imaging technique) measured at a minimum of two separate occasions.
  • History of cerebral infarction on brain MRI (overt stroke, or silent cerebral infarct).
  • History of two or more episodes of acute chest syndrome (ACS) in the 2-years period preceding enrollment.
  • History of two or more SCD related pain events requiring treatment with parenteral analgesics in the last 12 months.
  • History of two or more episodes of priapism (erection lasting ≥4 hours or requiring emergent medical care).
  • Administration of regular RBC transfusions (≥8 transfusions in the previous 12 months).
  • Evidence of progressive end organ damage (eg. cardiomyopathy, nephropathy, pulmonary hypertension etc) that in the opinion of the treating hematologist is not responsive to medical management and may benefit from an HCT. Such a determination must be made in writing by at least two independent hematologists and documented in the patient's electronic medical record prior to enrollment.

Donor

  • An at least single haplotype matched (≥ 3 of 6) family member.
  • negative
  • Not pregnant, as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).
  • Not breast feeding.
  • Donor should not have hemoglobinopathy. Donors with sickle cell trait are acceptable.
  • Regarding donation eligibility, is identified as either:
  • Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR.
  • Does not meet 21 CFR 1271 eligibility requirements but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.

Exclusion criteria

Exclusion Criteria:

Transplant Recipient

  • or Lansky performance score \<60.
  • Pregnant, as confirmed by positive serum or urine pregnancy test within 14 days prior to enrollment (if female).
  • Breast feeding.
  • Uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning. Patients with febrile illness or suspected minor infection should await clinical resolution prior to starting conditioning. Patients with confirmed seropositivity or positive NAAT for are excluded.
  • Serum conjugated (direct) >3x for age as per local laboratory. Participants with hyperbilirubinemia as the result of hyperhemolysis, or a severe drop in post blood transfusion, are not excluded as long as it downtrends and return to acceptable limits subsequently.
  • Left ventricular shortening fraction \<25% or \<40% by echocardiogram.
  • Estimated less than 50 mL/min/1.73m2.
  • Diffusion capacity of carbon monoxide (DLCO) \<35% (adjusted for hemoglobin) OR baseline oxygen saturation \<85% or PaO2 \<70.
  • Presence of anti-donor specific HLA antibodies unresponsive to desensitization.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    HAPSCD Treatment

    Drug: Cyclophosphamide 50mg · Drug: Abatacept · Drug: Alemtuzumab · Drug: Hydroxyurea · Drug: Thiotepa · Drug: Filgrastim · Drug: Sirolimus · Drug: Azathioprine · Radiation: TBI · Procedure: Hematopoietic Progenitor Cell Infusion

Interventions

06

What researchers measure

Primary outcomes

  1. GVHD-free and rejection free survival (GRFS)

    GRFS is defined as the time interval from transplant (graft infusion) until the first of grade III-IV acute GVHD, moderate or severe chronic GVHD, primary or secondary graft failure requiring second definitive therapy, and death occurs. GRFS will be calculated at 1-year, and 3-year post-transplant and reported as a percentage of the enrolled patients.

    Time frame: Up to 3 years after HCT

Secondary outcomes

  1. Overall survival (OS)

    Event for OS will include death due to any cause. OS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients.

    Time frame: Up to 3 years after HCT

  2. Disease-free survival (DFS)

    Events for DFS will include death due to any cause and recurrence of SCD symptoms or graft failure after HCT. DFS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients.

    Time frame: Up to 3 years after HCT

  3. Incidence and severity of acute and chronic GVHD

    Incidence of acute GVHD will be evaluated and reported at 1 month and, 3 months, and 6 months after HCT as a percentage of the enrolled patients. Incidence of chronic GVHD will be evaluated and reported at 6 months, 1 year and 3 years after HCT as a percentage of the enrolled patients

    Time frame: Up to 3 years after HCT

  4. Neutrophil and platelet engraftment

    The time to neutrophil and platelet engraftment will be reported in aggregate for all the participants using summary statistics.

    Time frame: Up to 6 months after HCT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2034, 96 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 96 months is above that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
Jun 1, 2026
StartActual
Sep 10, 2026
Primary completionEst.
Sep 2034
CompletionEst.
Sep 2035
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07616154
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 10, 2026
Primary completion
Sep 2034 (estimated)
Completion
Sep 2035 (estimated)
Last update
Nov 12, 2026

Study contacts

Akshay Sharma, MD
Contact
referralinfo@stjude.org
8662785833
Akshay Sharma, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Abatacept · Alemtuzumab · Hydroxyurea · Thiotepa · Filgrastim · Sirolimus · Azathioprine

Start the discussion